



PCORI's Hepatitis C Workshop

*Arlington, Virginia
October 17, 2014*

Patient-Centered Outcomes Research Institute



Breakout Sessions— Discussion and Ranking of CER Questions

Patient-Centered Outcomes Research Institute



3. Head-to-Head Trials

*Dr. Camilla Graham, MD
Assistant Professor of Medicine
National Viral Hepatitis Roundtable*

Patient-Centered Outcomes Research Institute

CER Question 1

- Which of two all-oral interferon-free strategies for the treatment of chronic genotype 1 hepatitis C infection, including sofosbuvir/ledipasvir and paritaprevir/ritonavir/ombitasvir/dasabuvir +/- ribavirin, will maximize sustained virologic response (SVR) and minimize adverse effects and harm?

CER Question 1

- Target condition
- Target population
- Compared interventions
- Proposed outcome measures (including patient-centered outcomes)
- Study design
- Feasibility of doing the study as outlined. Potential problems
- Possible results and how they might alter practice or policy
- Feasibility of scaling up the intervention to national-level adoption



CER Question 2

- Which of the available therapies – existing and recently introduced – for treatment of hep C demonstrate the best outcomes with the fewest side effects?

CER Question 2

- Target condition
- Target population
- Compared interventions
- Proposed outcome measures (including patient-centered outcomes)
- Study design
- Feasibility of doing the study as outlined. Potential problems
- Possible results and how they might alter practice or policy
- Feasibility of scaling up the intervention to national-level adoption



CER Question 3

- Would those failing one DAA-based combination regimen respond to another regimen?

CER Question 3

- Target condition
- Target population
- Compared interventions
- Proposed outcome measures (including patient-centered outcomes)
- Study design
- Feasibility of doing the study as outlined. Potential problems
- Possible results and how they might alter practice or policy
- Feasibility of scaling up the intervention to national-level adoption



CER Question 4

- What are the real-world rates of reinfection, particularly among IV drug users?

CER Question 4

- Target condition
- Target population
- Compared interventions
- Proposed outcome measures (including patient-centered outcomes)
- Study design
- Feasibility of doing the study as outlined. Potential problems
- Possible results and how they might alter practice or policy
- Feasibility of scaling up the intervention to national-level adoption





Lunch

12 – 12:30 PM

Patient-Centered Outcomes Research Institute



Breakout Sessions— Discussion and Ranking of CER Questions (cont'd)

Patient-Centered Outcomes Research Institute

Color Coding

- Neon Orange: Industry
- Neon Green: Clinicians
- Blue: Patients and Coalition
- Green: Researchers and Federal
- Yellow: Systems
- Red: Payers and Purchasers



Break

2 – 2:30 PM

Patient-Centered Outcomes Research Institute